An international team of researchers led by the University of California San Diego has developed a new strategy to enhance ...
Hosted on MSN11h
BlueRock accelerates Parkinson’s disease therapy to Phase IIIThe US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...
An international team of researchers led by the University of California San Diego has developed a new strategy to enhance ...
VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...
Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New ...
Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...
A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...
The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...
AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback